Tapering Antidepressant Medications

Introduction to Tapering

• The American Academy of Child and Adolescent Psychiatry suggests that SSRIs like escitalopram are associated with a discontinuation syndrome characterized by dizziness, fatigue, nausea, sensory disturbances, anxiety, and irritability when stopped abruptly 1
• Both escitalopram and SNRIs affect serotonin levels, and starting an SNRI without properly tapering escitalopram could potentially increase the risk of serotonin syndrome 1

Recommended Tapering Protocol

• Gradually reduce escitalopram over 2-4 weeks rather than stopping abruptly 1
• Begin the SNRI after completing the escitalopram taper or during the final stages of tapering when on a very low dose of escitalopram 1
• Standard initial doses of SNRIs (e.g., duloxetine 30mg daily, venlafaxine 37.5mg daily) should be used when starting after the taper 2, 3

Potential Complications to Monitor

• Serotonin syndrome risk increases if therapeutic doses of both medications overlap significantly 1, 4
• Symptoms of serotonin syndrome include mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity 4

Special Considerations

• Patients should be educated about the importance of not missing doses during the transition period 1

Common Pitfalls to Avoid

• Starting the SNRI at too high a dose while still on significant amounts of escitalopram 1
• Abrupt discontinuation, which significantly increases the risk of withdrawal symptoms 5